Targeting DNA damage response in HPV-related head and neck cancer
Official title: Targeting the DNA Damage Response in HPV+ Head and Neck Cancer
Funded at University of Pennsylvania · NIH-11117189 · Data updated 2026-11-12
This study is looking at how the HPV virus affects DNA in head and neck cancer and is testing a new treatment that could help patients avoid harsh side effects from standard therapies, aiming to make their treatment easier and more effective.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | June 17, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $248,999 |
| NIH project number | 5R00DE030194-06 |
| Project ID | NIH-11117189 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with HPV-positive head and neck squamous cell carcinoma.
✕Less likely to help
Patients with HPV-negative head and neck cancers or those with other unrelated malignancies may not benefit from this research.
What this research studies
This research focuses on understanding how the human papillomavirus (HPV) affects DNA damage response mechanisms in head and neck squamous cell carcinoma (HNSCC). The study aims to explore the role of HPV's E6 and E7 proteins in disrupting tumor suppressor pathways and causing genomic instability. By investigating the effects of a specific inhibitor called AZD1775 on HPV+ HNSCC tumors, the research seeks to develop targeted therapies that could reduce the need for traditional chemoradiotherapy, which often leads to long-term side effects for patients. The ultimate goal is to improve treatment outcomes and quality of life for patients with this type of cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatment options for patients with HPV-positive head and neck cancer.
How similar studies have gone: Previous research has shown promising results with similar approaches targeting DNA damage response in cancer treatment, indicating potential for success in this area.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Diab, Ahmed Mohamed — University of Pennsylvania
- Study coordinator: Diab, Ahmed Mohamed
Related research
Other NIH-funded projects on the same topics.
-
Combined Imaging and RNA Markers to Predict Head and Neck Cancer Recurrence
A research project aims to use imaging and RNA data to better predict if head and neck cancer will come back, helping doctors tailor treatments for patients.
-
Biomarker to guide treatment in head and neck cancer
A biomarker test using tumor samples is being developed to predict recurrence risk in oral cancers and help tailor treatment.
-
Intensive dental care during cancer follow-up to protect teeth after head and neck radiation
A program delivered in oncology clinics to provide fluoride varnish and dental follow-up aims to reduce tooth decay and improve oral health and quality of life for head and neck cancer patients after radiation therapy.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A computer program helps plan radiation therapy for cervical and head-and-neck cancer patients to make treatments faster and more accurate.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A United Kingdom study is testing AI software that helps plan radiotherapy for cervical and head-and-neck cancer patients to save time and reduce the workload for clinicians in low-resource settings.
-
AI-powered radiotherapy planning for cervical and head-and-neck cancer
A UK research team is testing an AI-based software to automatically outline cancer areas and plan radiation beams to speed up treatment for cervical and head-and-neck cancers in LMICs.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.